Predicting the impact of monoclonal antibodies & vaccines on antimicrobial resistance


Start Date
End Date
IMI2 - Call 23
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
6 500 000
EFPIA in kind
2 750 000
Total Cost
9 250 000


Antimicrobial resistance (AMR) is a major threat to human and animal health worldwide. Vaccines and monoclonal antibodies (mAbs, laboratory-made antibodies similar to those your body makes in response to an infection) could play a key role in the fight against AMR. Developing vaccines and mAbs is costly and time-consuming, and so choices need to be made on which vaccines / mAbs should be prioritised for development. However, there are many drug-resistant infections and potential vaccines and mAbs out there, and right now it is very difficult to determine which vaccines / mAbs would have the greatest impact on the burden of AMR and which would only have a limited impact.

The aim of PRIMAVERA is to develop mathematical models and an epidemiological repository that will facilitate the assessment of different vaccines and mAbs in terms of their likely impact on AMR.

PRIMAVERA will set up an open access, web-based platform that will allow the wider scientific and healthcare communities to freely access and use the models and repository. For example, policy makers and healthcare authorities could use the platform to make informed decisions on which vaccines and mAbs should be prioritised. A project sustainability plan will ensure long-term access to the project results, including the models, once the project has finished.

PRIMAVERA is part of the AMR Accelerator Programme.

Participants Show participants on map

EFPIA companies
  • Glaxosmithkline Biologicals SA, Rixensart, Belgium
  • Janssen Vaccines & Prevention BV, Leiden, Netherlands
  • Pfizer Limited, Sandwich, Kent , United Kingdom
Universities, research organisations, public bodies, non-profit groups
  • Danmarks Tekniske Universitet, Kgs. Lyngby, Denmark
  • Department of Health, Leeds, United Kingdom
  • Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany
  • European Vaccine Initiative E.V, Heidelberg, Germany
  • Institut Pasteur, Paris, France
  • Instituto De Salud Carlos Iii, Madrid, Spain
  • Lietuvos Sveikatos Mokslu Universiteto Ligonine Kauno Klinikos, Kaunas, Lithuania
  • Servicio Andaluz De Salud, Sevilla, Spain
  • Universita Degli Studi Di Verona, Verona, Italy
  • Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
  • Universite De Geneve, Genève 4, Switzerland
  • Universite Grenoble Alpes, Grenoble, France
  • University of Oxford, Oxford, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Ares Genetics GMBH, Wien, Austria
  • Life Science Network Ggmbh, Heidelberg, Germany
Project coordinator
Irina Meln
European Vaccine Initiative Ewiv